Madrigal builds in MASH with $4.4bn+ Ribo alliance
Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.
Newsletters and Deep Dive digital magazine
Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.
The UK government has asked the NHS to start putting together the platforms to allow anonymised primary care patient data to be used by researchers.
Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.
Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.
Antimicrobial resistance (AMR) is a growing global health crisis.
Editor's Picks
Newsletters and Deep Dive
digital magazine